Expectations of Pain and Accompanying Symptoms during Cancer Treatment

Wells, Nancy; Sandlin, Victoria

doi:10.1007/s11916-012-0272-0

Cited by 4 publications

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that post-operative pain was a stark complication of TAE. In this case, pain sensation could be attributed to the acute ischemia and necrosis of solid tumor, cell debris-induced inflammatory, and abnormal tissue tension [ 14 – 16 ]. To relieve pain, these patients are conventionally given oral nonsteroidal anti-inflammatory drugs (NSAID) or opioids [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

One-step fabrication of lidocaine/CalliSpheres® composites for painless transcatheter arterial embolization

et al. 2022

View full text Add to dashboard Cite

Background Transcatheter arterial embolization (TAE) is one of the first-line treatments for advanced hepatocellular cancer. The pain caused by TAE is a stark complication, which remains to be prevented by biomedical engineering methods. Methods Herein, a commercial embolic agent CalliSpheres® bead (CB) was functionally modified with lidocaine (Lid) using an electrostatic self-assembly technique. The products were coded as CB/Lid-n (n = 0, 5, 10, corresponding to the relative content of Lid). The chemical compositions, morphology, drug-loading, and drug-releasing ability of CB/Lid-n were comprehensively investigated. The biocompatibility was determined by hemolysis assay, live/dead cell staining assay, CCK8 assay, immunofluorescence (IHC) staining assay and quantitative real-time PCR. The thermal withdrawal latency (TWL) and edema ratio (ER) were performed to evaluate the analgesia of CB/Lid-n using a plantar inflammation model. A series of histological staining, including immunohistochemistry (IL-6, IL-10, TGF-β and Navi1.7) and TUNEL were conducted to reveal the underlying mechanism of anti-tumor effect of CB/Lid-n on a VX2-tumor bearing model. Results Lid was successfully loaded onto the surface of CalliSpheres® bead, and the average diameter of CalliSpheres® bead increased along with the dosage of Lid. CB/Lid-n exhibited desirable drug-loading ratio, drug-embedding ratio, and sustained drug-release capability. CB/Lid-n had mild toxicity towards L929 cells, while triggered no obvious hemolysis. Furthermore, CB/Lid-n could improve the carrageenan-induced inflammation response micro-environment in vivo and in vitro. We found that CB/Lid-10 could selectively kill tumor by blocking blood supply, inhibiting cell proliferation, and promoting cell apoptosis. CB/Lid-10 could also release Lid to relieve post-operative pain, mainly by remodeling the harsh inflammation micro-environment (IME). Conclusions In summary, CB/Lid-10 has relatively good biocompatibility and bioactivity, and it can serve as a promising candidate for painless transcatheter arterial embolization.

show abstract

Section: Introductionmentioning

confidence: 99%

One-step fabrication of lidocaine/CalliSpheres® composites for painless transcatheter arterial embolization

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Despite the options of using analgesics and other modalities, pain continues to be problematic in more than 50% of cancer patients (van den Beuken‐van Everdingen et al, ). Cancer pain is a multidimensional experience comprised of many factors, including distress and perceived control over pain, all of which affect the patient's functional status (Leung, Pachana, & McLaughlin, ; Schaller, Larsson, Lindblad, & Liedberg, ; Vallerand, Templin, Hasenau, & Riley‐Doucet, ; Wells, ; Wells & Sandlin, ). Although distress is experienced by all patients with cancer at some point during diagnosis and treatment (Hulbert‐Willams, Storey, & Wilson, ; National Comprehensive Cancer Network, ), in a study of ambulatory patients with cancer‐related pain, general symptom distress was found to be low, whereas, pain‐related distress was high (Vallerand, Templin et al, ).…”

Section: Introductionmentioning

confidence: 99%

Modifiable pathways from pain to functional status: Confirmatory baseline results from a randomised trial of African American patients with cancer pain

et al. 2019

View full text Add to dashboard Cite

Objective This study tested a model of cancer‐related pain and functional status in African American patients, including beliefs about the ability to control pain as a key determinant of distress and functional status. Methods Baseline data from a randomised clinical trial consisting of clinical and patient‐reported outcomes were used. Participants were 228 African American patients experiencing moderate to severe pain within the past 2 weeks. The model comprised four latent constructs: pain, perceived control over pain, pain‐related distress and functional status. Confirmatory factor analysis was used to validate the factor structure of the measurement model. Structural equation modelling was used to estimate direct and mediated effects. Results The measurement model fit well (RMSEA = 0.06, SRMR = 0.05) with all loadings significant (p < 0.05). The structural model also fit well (RMSEA = 0.04, SRMR = 0.05). The complex mediated pathway from pain to functional status through perceived control over pain and pain‐related distress was strong and significant (specific indirect effect = −0.456, p = 0.004). Mediation by perceived control accounted for a 47% reduction of the effects of pain on functional status. Conclusion If these results hold up longitudinally, interventions to increase perceived control over pain have the potential to improve functional status by decreasing pain‐related distress.

show abstract

Improving Functional Status in African Americans With Cancer Pain: A Randomized Clinical Trial

Vallerand

Hasenau

Robinson‐Lane

et al. 2018

ONF

View full text Add to dashboard Cite

show abstract

Expectations of Pain and Accompanying Symptoms during Cancer Treatment

Cited by 4 publications

References 57 publications

One-step fabrication of lidocaine/CalliSpheres® composites for painless transcatheter arterial embolization

One-step fabrication of lidocaine/CalliSpheres® composites for painless transcatheter arterial embolization

Modifiable pathways from pain to functional status: Confirmatory baseline results from a randomised trial of African American patients with cancer pain

Improving Functional Status in African Americans With Cancer Pain: A Randomized Clinical Trial

Contact Info

Product

Resources

About